Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 11/20 | 0.70 |
| ▸ | CTSK | P43235 | 10/20 | 0.70 |
| ▸ | CTSB | P07858 | 4/20 | 0.70 |
| ▸ | CTSL | P07711 | 2/20 | 0.70 |
| ▸ | AKT1 | P31749 | 1/20 | 0.60 |
| ▸ | ACE | P12821 | 1/20 | 0.60 |
| ▸ | REN | P00797 | 2/20 | 0.58 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19513108 | 1.00 | CTSS (0.70) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL20516388 | 0.88 | CTSS (0.68) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL20516385 | 0.88 | CTSS (0.68) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL5556757 | 0.88 | CTSS (0.71) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL3004474 | 0.88 | CTSS (0.71) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL3004471 | 0.88 | CTSS (0.71) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL4797141 | 0.88 | CTSS (0.53) | CTSSCTSKCTSBCTSLATM | |
| SCHEMBL4797147 | 0.88 | CTSS (0.53) | CTSSCTSKCTSBCTSLATM | |
| SCHEMBL11568520 | 0.87 | CTSS (0.67) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL6163323 | 0.86 | CTSS (0.73) | CTSSCTSKCTSBCTSLAKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1134213-B1 | Process for the preparation of substituted N-(indole-2-carbonyl)- glycinamides | PFIZER (US) | 2005-11-02 | — | — | EP | disclosed |
| US-6960575-B2 | For use as inhibitors of chymase | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2005-11-01 | — | — | US | disclosed |
| US-20040097496-A1 | Novel thiazine derivatives | SANTEN PHARMACEUTICAL CO.,LTD. (JP) | 2004-05-20 | — | — | US | disclosed |
| US-6713472-B1 | 2-OXO-1,2,3,4-TETRAHYDROPYRAZINE DERIVATIVES; CHYMASE INHIBITORS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2004-03-30 | — | — | US | disclosed |
| EP-1211249-A1 | NOVEL THIAZINE OR PYRAZINE DERIVATIVES | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-06-05 | — | — | EP | disclosed |
| EP-0832065-B1 | SUBSTITUTED N-(INDOLE-2-CARBONYL)-GLYCINAMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER (US) | 2001-10-10 | — | — | EP | disclosed |
| EP-1134213-A2 | Process for the preparation of substituted N-(indole-2-carbonyl)- glycinamides | PFIZER INC. (US) | 2001-09-19 | — | — | EP | disclosed |
| US-6277877-B1 | GLYCOGEN PHOSPHORYLASE INHIBITOR; ANTIDIABETIC AGENTS | PFIZER, INC. | 2001-08-21 | — | — | US | disclosed |
| US-6107329-A | HYPOTENSIVE AGENTS; CARDIOVASCULAR DISORDERS | PFIZER, INC. (US) | 2000-08-22 | — | — | US | disclosed |
| EP-0832065-A1 | SUBSTITUTED N-(INDOLE-2-CARBONYL)-GLYCINAMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER INC. (US) | 1998-04-01 | — | — | EP | disclosed |
| WO-1996039384-A1 | SUBSTITUTED N-(INDOLE-2-CARBONYL)-GLYCINAMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER, INC. (US) | 1996-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097496-A1 | Novel thiazine derivatives | CMA1, TPSD1, HRH4 | CTSS 14/4885CTSK 29/4885CTSB 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.